Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Siga Technologies
Pharma
Siga's Tpoxx misses the mark in another mpox study
The antiviral didn't demonstrate efficacy in patients with the clade 2 mpox strain, matching August results in patients with clade 1 mpox.
Zoey Becker
Dec 12, 2024 8:55am
Siga's Tpoxx misses the mark in mpox study amid renewed outbreak
Aug 15, 2024 11:35am
US renews $113M deal with Siga to supply mpox antiviral Tpoxx
Jul 19, 2024 10:35am
Siga snares $138M US government contract to supply smallpox drug
Jul 31, 2023 10:41am
FDA says overuse of Siga's Tpoxx could render it ineffective
Sep 15, 2022 10:54am
U.S. lines up AmerisourceBergen for monkeypox meds
Sep 7, 2022 9:04am
